tiprankstipranks
Trending News
More News >
West Pharmaceutical Services, Inc. (WST)
NYSE:WST
US Market
Advertisement

West Pharmaceutical Services (WST) Earnings Dates, Call Summary & Reports

Compare
807 Followers

Earnings Data

Report Date
Oct 23, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
1.68
Last Year’s EPS
1.85
Same Quarter Last Year
Based on 9 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Jul 24, 2025|
% Change Since: -5.59%|
Earnings Call Sentiment|Positive
The earnings call reflected strong performance in key growth areas like HVP components and delivery devices, leading to upward revisions in revenue and EPS guidance for 2025. However, challenges such as slow growth in Standard Products, persistent destocking in generics, and tariff uncertainties remain concerns.
Company Guidance -
Q3 2025
During the Q2 2025 earnings call, West Pharmaceutical Services provided several key metrics and guidance updates for the fiscal year. The company reported a 9.2% increase in net sales, with a 6.8% rise on an organic basis, driven by robust growth in GLP-1 elastomer products, which accounted for 8% of total revenues in the quarter. The Proprietary Products segment saw an 8.4% organic growth, bolstered by an 11.3% increase in HVP components. West's Contract Manufacturing segment experienced a 0.5% organic revenue increase, with total net sales reaching $766.5 million. The company raised its full-year 2025 guidance, now expecting net sales between $3.04 billion and $3.06 billion, and adjusted diluted EPS in the range of $6.65 to $6.85. This upward revision is attributed to strong Q2 performance, ongoing momentum in HVP components, and a favorable foreign exchange environment. Adjusted gross profit margin improved by 290 basis points year-over-year to 35.7%, with adjusted operating profit margin up by 230 basis points to 20.3%. Additionally, full-year CapEx guidance remains at $275 million, with expected tariffs estimated to impact the business by $15 million to $20 million in 2025.
Strong Revenue Growth
Net sales increased 9.2% in Q2 2025, and 6.8% on an organic basis, driven by robust GLP-1 elastomer growth and HVP components. Adjusted diluted EPS increased by 21.1% compared to Q2 2024.
Proprietary Products Segment Performance
Proprietary Products segment saw an 8.4% organic growth, with HVP components increasing 11.3% in the quarter.
HVP Delivery Devices Growth
Revenues from HVP Delivery Devices increased by 30% in Q2 2025, driven by Daikyo Crystal Zenith containment and administration systems.
Upgraded Guidance for 2025
Full-year 2025 revenue guidance increased to $3.04 billion to $3.06 billion from the previous range of $2.945 billion to $2.975 billion.
Improving Gross Profit Margins
Gross profit margin increased by 290 basis points year-over-year to 35.7% in Q2 2025.
Positive Currency Impact
A favorable foreign currency environment contributed a $16.5 million tailwind to revenue in Q2 2025.

West Pharmaceutical Services (WST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

WST Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 23, 2025
2025 (Q3)
1.68 / -
1.85
Jul 24, 2025
2025 (Q2)
1.51 / 1.84
1.5221.05% (+0.32)
Apr 24, 2025
2025 (Q1)
1.23 / 1.45
1.56-7.05% (-0.11)
Feb 13, 2025
2024 (Q4)
1.72 / 1.82
1.83-0.55% (-0.01)
Oct 24, 2024
2024 (Q3)
1.50 / 1.85
2.16-14.35% (-0.31)
Jul 25, 2024
2024 (Q2)
1.74 / 1.52
2.11-27.96% (-0.59)
Apr 25, 2024
2024 (Q1)
1.27 / 1.56
1.98-21.21% (-0.42)
Feb 15, 2024
2023 (Q4)
1.78 / 1.83
1.773.39% (+0.06)
Oct 26, 2023
2023 (Q3)
1.86 / 2.16
2.036.40% (+0.13)
Jul 27, 2023
2023 (Q2)
1.93 / 2.11
2.47-14.57% (-0.36)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

WST Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 24, 2025
$227.31$279.10+22.78%
Apr 24, 2025
$217.96$210.38-3.48%
Feb 13, 2025
$321.96$198.91-38.22%
Oct 24, 2024
$285.79$329.90+15.43%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does West Pharmaceutical Services, Inc. (WST) report earnings?
West Pharmaceutical Services, Inc. (WST) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).
    What is West Pharmaceutical Services, Inc. (WST) earnings time?
    West Pharmaceutical Services, Inc. (WST) earnings time is at Oct 23, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is WST EPS forecast?
          WST EPS forecast for the fiscal quarter 2025 (Q3) is 1.68.

            West Pharmaceutical Services (WST) Earnings News

            West Pharmaceutical Stock (NYSE:WST): Analyst Reaffirms Buy Rating Post Q3 Results
            Premium
            Market News
            West Pharmaceutical Stock (NYSE:WST): Analyst Reaffirms Buy Rating Post Q3 Results
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis